奥拉西坦对高血压脑出血患者神经功能和认知功能的影响

Effect of Oxiracetam on Neurological Function and Cognitive Function in Patients with Hypertensive Intracerebral Hemorrhage

目的探讨奥拉西坦对高血压脑出血(HICH)患者神经功能、认知功能恢复的影响。方法选取湖北医药学院附属太和医院2016年3月至2017年3月收治的HICH血肿清除术后患者90例,采用随机数字表法分为试验组和对照组,各45例。两组患者均给予术后基础治疗及康复治疗,试验组同时给予奥拉西坦治疗,两组均治疗3周。结果两组患者的神经功能缺损评分(NIHSS)均较治疗前显著降低(P<0.05),巴氏评分(Barthel)、长谷川痴呆量表评分(HDS)均较治疗前显著升高(P<0.05),且试验组均显著优于对照组(P<0.05);两组患者的血清S100β蛋白、基质金属蛋白酶组织抑制因子-1(TIMP-1)、基质金属蛋白酶9(MMP-9)、神经元特异性烯醇化酶(NSE)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)水平均较治疗前显著降低(P<0.05),且试验组均显著优于对照组(P<0.05);治疗后3个月,试验组患者预后良好率(68.89%)与对照组(55.56%)相当(P>0.05)。结论奥拉西坦对HICH患者的神经功能、认知功能的恢复具有重要的临床价值。

Objective To investigate the effect of oxiracetam on the recovery of neurological function and cognitive function in patients with hypertensive intracerebral hemorrhage(HICH).Methods Totally 90 patients with HICH after hematoma evacuation admitted to Taihe Hospital Affiliated to Hubei Medical College from March 2016 to March 2017 were selected and randomly divided into the experimental group and the control group,45 cases in each group.The patients in the two groups were given basic treatment and rehabilitation treatment after operation,on this basis,the patients in the experimental group were given oxiracetam.Both groups were treated for 3 weeks.Results After treatment,the National Institutes of Health Stroke Scale(NIHSS)scores in the two groups were significantly lower than those before treatment(P<0.05),while the Barthel scores and Hasegawa Dementia Scale(HDS)scores in the two groups were significantly higher than those before treatment(P<0.05),and those in the experimental group were significantly better than those in the control group(P<0.05).After treatment,the levels of serum S100βprotein,tissue inhibitor of tissue factor-1(TIMP-1),matrix metalloproteinase-9(MMP-9),neuron-specific enolase(NSE),hypersensitive C-reactive protein(hs-CRP),tumor necrosis factor-α(TNF-α)in the two groups were significantly lower than those before treatment(P<0.05),and those in the experimental group were significantly better than those in the control group(P<0.05).Three months after treatment,the good prognosis rate of the experimental group was 68.89%,which was similar to 55.56%of the control group(P>0.05).Conclusion Oxiracetam has important clinical value in the recovery of neurological function and cognitive function in patients with HICH.